Molecular pharmacology is a research field that investigates the molecular and cellular interactions of drugs and other chemical agents with biological systems. It focuses on elucidating the precise mechanisms of drug action, target identification, and the molecular basis of therapeutic and toxic effects to advance understanding and development of therapeutic interventions.
Ontological type
Core Mechanisms
Experimental Techniques
Drug Target Classes
Quantitative Receptor Pharmacology
1939 - 1977
Molecular Receptor Architecture
1978 - 1991
Structure-Guided Multitarget Pharmacology
1992 - 2023
Quantitative Receptor Pharmacology era
John R. Vane [1] was a pivotal figure in quantitative pharmacology, with stints at Yale University [3] and the University of Cambridge [4] shaping the era. His notable contribution in this era came from the 1971 paper Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs [7], which linked prostaglandin biology to drug action and helped standardize quantitative pharmacodynamic thinking. Folke Sjöqvist [2] contributed to the quantitative pharmacology narrative through work at Johns Hopkins University [5] and Washington University in St. Louis [6] during this era. His 1970 paper Plasma protein binding of diphenylhydantoin in man; Interaction with other drugs and the effect of temperature and plasma dilution [8] highlighted how plasma protein interactions shape drug distribution and exposure, a key theme of this era's integration of pharmacokinetics with pharmacodynamics.
Molecular Receptor Architecture era
Michael M. Gottesman [1] is associated with the University of California, Los Angeles [3] and Heidelberg University [4] during the Molecular Receptor Architecture era. His 1987 work, Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues [7], mapped tissue distribution of the P-glycoprotein transporter and highlighted its role in multidrug resistance, a finding that anchored mechanistic pharmacology in transporter biology. Thomas M. Jessell [2] is associated with Harvard University [5] and Boston University [6] during this era. His 1988 work, Molecular Characterization of a Functional cDNA Encoding the Serotonin 1c Receptor [8], represents a key advance in cloning GPCRs and linking primary sequence with pharmacological specificity and signaling, shaping mechanistic pharmacology in this era.
Structure-Guided Multitarget Pharmacology era
Arthur J. Olson [1] is associated with Rockefeller University [3] and Washington University in St. Louis [4] during this era. His work on AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility [7] advanced structure-guided ligand discovery and multitarget pharmacology in this era. David E. Moller [2] is associated with Harvard University [5] and University of California, San Francisco [6] in this era. His 2001 paper, Role of AMP-activated protein kinase in mechanism of metformin action [8], illuminated how energy-sensing pathways mediate drug effects, informing target engagement and polypharmacology strategies in metabolic disease.